Infections in patients with chronic lymphocytic leukemia

被引:7
作者
Guarana, Mariana [1 ]
Nucci, Marcio [1 ,2 ,3 ]
机构
[1] Univ Fed Rio de Janeiro UFRJ, Rio De Janeiro, RJ, Brazil
[2] Grp Oncoclin, Rio De Janeiro, RJ, Brazil
[3] Hosp Univ Clementino Fraga Filho, Rua Rodolpho Paulo Rocco 255 Sala 4A 12, BR-21941913 Rio De Janeiro, Brazil
关键词
Chronic lymphocytic leukemia; Leukemia; Chronic lymphoid leukemia; Infection; Immunity; LONG-TERM; RITUXIMAB; FLUDARABINE; COMPLICATIONS; THERAPY; PHASE-3;
D O I
10.1016/j.htct.2023.05.006
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Introduction: Infection is a major complication in patients with chronic lymphocytic leukemia (CLL). Newly diagnosed patients are at high risk of developing infection caused by encapsulated bacteria, such as Streptococcus pneumoniae and Haemophylus influenzae. Method and Results: However, once treatment is initiated, the spectrum of pathogens causing infection broadens, depending on the treatment regimens. With disease progression, cumulative immunosuppression occurs as a consequence of multiple treatment lines and the risk of infection further increases. On the other hand, the use of targeted therapies in the treatment of CLL have brought new risks of infection, with an increased incidence of invasive fungal diseases, particularly aspergillosis, in patients receiving Bruton kinase inhibitors.Conclusion: In this article, we review the epidemiology of infection in patients with CLL, taking into account the treatment regimen, and briefly discuss the management of infection.& COPY; 2023 Associacao Brasileira de Hematologia, Hemoterapia e Terapia Celular. Published by Elsevier Espana, S.L.U. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
引用
收藏
页码:387 / 393
页数:7
相关论文
共 61 条
[31]   Screening for and management of hepatitis B virus reactivation in patients treated with anti-B-cell therapy [J].
Kusumoto, Shigeru ;
Tobinai, Kensei .
HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM, 2014, :576-583
[32]   Effector and regulatory B cells: modulators of CD4+ T cell immunity [J].
Lund, Frances E. ;
Randall, Troy D. .
NATURE REVIEWS IMMUNOLOGY, 2010, 10 (04) :236-247
[33]   ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Agents targeting lymphoid cells surface antigens [I]: CD19, CD20 and CD52) [J].
Mikulska, M. ;
Lanini, S. ;
Gudiol, C. ;
Drgona, L. ;
Ippolito, G. ;
Fernandez-Ruiz, M. ;
Salzberger, B. .
CLINICAL MICROBIOLOGY AND INFECTION, 2018, 24 :S71-S82
[34]   FDA: Increased HBV Reactivation Risk With Ofatumumab or Rituximab [J].
Mitka, Mike .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2013, 310 (16) :1664-1664
[35]  
MOLICA S, 1993, HAEMATOLOGICA, V78, P374
[36]  
Morrison V.A., 2022, Prevention of infections in patients with chronic lymphocytic leukemia
[37]  
Morrison VA, 1998, SEMIN ONCOL, V25, P98
[38]   Patients with CLL have a lower risk of death from COVID-19 in the Omicron era [J].
Niemann, Carsten U. ;
da Cunha-Bang, Caspar ;
Helleberg, Marie ;
Ostrowski, Sisse R. ;
Brieghel, Christian .
BLOOD, 2022, 140 (05) :445-450
[39]  
Nucci M, 2023, Infections in patients with multiple myeloma
[40]  
Nucci M, 2013, Neoplastic diseases of the blood, P1149